NEWTON, Mass.--(BUSINESS WIRE)--Life Image, the world's largest global network for sharing clinical and imaging data that is powered by industry leading interoperability standards, and Mendel.ai, a novel AI platform built to turbocharge oncology clinical research by rigorously examining every piece of EMR data, today announced a new strategic partnership that will facilitate the adoption and enhancement of AI in site selection and patient recruitment for oncology trials.
This new engagement will advance the use of Mendel Brain, which helps life sciences and research facilities by analyzing clinical data at a site location to identify patient cohorts for a given protocol. Mendel Brain yields 30 to 50 percent more patients while decreasing the elapsed time between patient eligibility and identification to minutes compared to conventional pre-screening practices, which can take months or even years. It can also proactively identify potential trials for patients by comparing their EMR data to an industry-leading trial database curated from over 40,000 sources.
Mendel Brain will be offered as a component of the Life Image Interoperability Suite to deliver additional value to its large network of research hospitals. With the depth and breadth of Life Image’s network of Academic Medical Centers (AMC), the Mendel Brain solution is in high demand to reduce the administrative burdens of clinical trial participation. In addition, the ease of interoperability and integration available through Life Image will help accelerate the adoption and application of Mendel Brain while providing greater access to clinical data including imaging data to help increase accuracy in patient selection.
“Imagine the Internet without a search engine — all of the information you need is there but you don’t know how to find it — and in many ways that’s where we are in the world of clinical trial research,” said Dr. Karim Galil, Founder, Mendel. “Identifying the right patient populations and research sites can be incredibly time consuming and cost intensive, and often falls short when it comes to reaching all of the patients who could contribute to and benefit from critical research. There is enormous opportunity for AI to revolutionize the clinical trial recruitment process, dramatically improve efficiency, and reduce many unnecessary costs. Clinical data available at scale and through a variety of sites globally is a critical piece of the puzzle to advancing Real World Data applications and enabling precision medicine.”
This new partnership follows Life Image’s recent re-launch announcement, which included the release of its new Interoperability Suite. Life Image’s interoperable solution, which integrates into existing workflows, orchestrates the flow of more than 10 million clinical encounters per month, connecting 1,500 U.S. facilities, 8,000 affiliated sites, 150,000 U.S. providers, and 58,000 global clinics with a broader ecosystem of patients, life sciences, medical device companies, and telehealth companies.
“Assembling clinical trials has long posed significant challenges for both our core customers as well as the healthcare industry as a whole,” said Matthew A. Michela, President and CEO, Life Image. “EHRs, imaging, lab, and other systems in the clinical setting have the information we need to find the most appropriate patient cohorts, but that data needs to be interoperable and searchable to have utility. This important partnership with Mendel allows us to offer our network, interoperability, and imaging expertise to augment Mendel Brain. Additionally, our large market penetration with research-oriented health systems will help make this leading solution available to easily integrate it within a hospital’s systems. Mendel Brain and our interoperable global network, together, will help us leap ahead in our quest to solve another of healthcare’s biggest challenges.”
According to research from Accenture, AI-powered clinical trial identifier applications are projected to save the healthcare industry $13B by 2026. This strategic partnership between Life Image and Mendel directly addresses this growing demand by combining Life Image’s extensive interoperable network of imaging and other clinical data with Mendel’s novel AI capabilities. Life sciences organizations will benefit from improved access and search functionality via Life Image’s global network to better pair patients and patient cohorts with clinical trials, while reducing the administrative and cost burdens associated with this research.
Life Image and Mendel will be attending the 2018 Radiological Society of North America (RSNA) Annual Meeting, scheduled for Nov. 25-30 in Chicago, Illinois. Visit Life Image at booth #1553 to learn more about how this new partnership will improve clinical trial recruitment and outcomes by furthering AI adoption in clinical research. To set up media interviews with executives from Life Image and Mendel at RSNA, please contact Ashley Owen, aowen@ariamarketing.com.
About Life Image
With its beginnings in medical image exchange, Life Image now orchestrates the flow of any and all clinical information across the patient’s journey, in real time, to help care teams and researchers make informed decisions. Founded in 2008, Life Image has spent the past decade innovating and building an interoperable network ecosystem connecting hospitals, physicians, patients, pharmaceuticals, medical device, telehealth and EHRs. Today, the Life Image network connects over 1,500 facilities in the United States and 8,000 affiliated sites, including 7 of the top 10 U.S. hospitals, with 150,000 U.S. providers and 58,000 clinics globally.
For more information about Life Image, please visit: www.lifeimage.com, and check out our blog and follow us on Twitter, Facebook, and LinkedIn.
About Mendel.ai
Mendel.ai is the breakthrough artificial intelligence engine and technology powering Mendel Health. Mendel Health is a for-profit corporation headquartered in San Francisco, CA that uses novel AI technology to sift through unstructured data in medical literature as well as patient health records, in order to suggest evidence-based treatment options and unlock a variety of other Real World Data applications. The company is currently focused on oncology and cancer patient populations. Please visit www.mendel.ai for more information about the company and technology.
